Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06215495
Other study ID # 2024-KY-010-01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 18, 2024
Est. completion date June 1, 2027

Study information

Verified date January 2024
Source Zhujiang Hospital
Contact Yujing Tan, Doctor
Phone +8613560347303
Email tanyujing-1981@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main question it aims to answer are: 1. whether the new target delineation scheme can improve Progression-free Survival 2. whether it can reduce the incidence of radiation complications in high-grade glioma patients. Participants in trial group will be performed radiotherapy of new target delineation method after the completion of the operation within 4-6 weeks., while participants in the control group be performed radiotherapy of EORTC(European organisation for research and treatment of cancer) target delineation method.Temozolomide 75 mg / ( m² · d ) will be given to both groups of patients during radiotherapy. After radiotherapy, its dose changes to 150 ~ 200 mg / ( m² · d ) for 5 days and stopped for 23 days as a cycle. There are 6 cycles in total.


Recruitment information / eligibility

Status Recruiting
Enrollment 88
Est. completion date June 1, 2027
Est. primary completion date May 28, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. High-grade glioma (2021 WHO grade III or IV) 2. Age between 18-65 years old, Karnofsky performance status (KPS) score = 70 3. result of pregnancy test being negative within 7 days before enrollment, only applicable to women with reproductive potential 4. The patient voluntarily joined this study and signed an informed consent form 5. Willing to return for follow-up 6. Willing to provide tissue and blood samples for this research 7. Surgical treatment was completed without any postoperative complications (such as consciousness disorders, hematomas, lung infection and cardiac insufficiency) 8. Radiotherapy within 4-6 weeks after surgery 9. No contraindications for taking temozolomide Exclusion Criteria: 1. Low-grade glioma(2021 WHO grade I or II) 2. had or having other type of malignant cancers 3. not having been performed gross total resection of tumor 4. Severe active comorbidities, systemic diseases or other serious comorbidities that would render the patient unsuitable for participation in this study or seriously interfere with the appropriate evaluation of the safety and toxicity of the prescribed regimen in the judgment of the investigator, including but not limited to persistent or active infections, symptomatic congestive heart failure, unstable angina pectoris, arrhythmia, or mental illness; 5. Baseline MRI indicates a previous or recent risk of cerebral hemorrhage or hernia; 6. Pregnancy or lactation, or pregnancy or childbirth during the expected trial period(from pre-screening or screening visits until 120 days after the last trial treatment) 7. Unable to perform brain magnetic resonance imaging; 8. Allergic to CT contrast agent, unable to perform enhanced CT examination; 9. Remote transfer; 10. Medical contraindications for receiving radiation therapy, such as active systemic lupus or scleroderma

Study Design


Intervention

Radiation:
reduced target volume
Delineate residual tumor(GTVp) and tumor bed(GTVtb) on enhanced contrast CT-MRI(T2 fluid attenuated inversion recovery, T2 FLAIR) fusion images. GTVtb and GTVp are expanded by 1cm to CTV_6000. The clinical target volume_6000 cGy (CTV_6000) is partially reduced beyond the skull and midline. According to the CT-MRI(T2 FLAIR) fusion images, the edema area that cannot be seen on contrast-enhanced CT and only can be seen on MRI should be included. If CTV_6000 includes thalamus, basal ganglia, brainstem or motor cortex, dose of these areas will be limited no more than 54Gy
EORTC (European organisation for research and treatment of cancer) target volume
delineate according to EORTC guideline

Locations

Country Name City State
China southern medical university affiliated Zhujiang Hospital Guangzhou

Sponsors (1)

Lead Sponsor Collaborator
Zhujiang Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary progression-free survival confirm if the participant's cancer progresses or he/she dies every time back to the hospital during screening and follow-up From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years
Secondary overall survival confirm if the participant dies every time back to the hospital during screening and follow-up From date of randomization until the date of death from any cause, assessed up to 3 year
Secondary European organisation for research and treatment of cancer QLQ-C30 (EORTC-QLQ-C30) EORTC-QLQ-C30 questionnaire through study completion, up to 3 years
Secondary radiotherapy complication incidence through study completion, up to 3 years
See also
  Status Clinical Trial Phase
Completed NCT04059809 - Photobiomodulation for Breast Cancer Radiodermatitis Phase 2/Phase 3
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT02058550 - Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy Phase 1
Completed NCT01434290 - Radiation Therapy in Treating Patients With Prostate Cancer Phase 2
Completed NCT01399372 - Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma Phase 2
Active, not recruiting NCT00087815 - Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain N/A
Completed NCT01407770 - Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer
Completed NCT00003313 - Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer Phase 3
Completed NCT03783364 - Pre- or Postoperative Accelerated Radiotherapy N/A
Enrolling by invitation NCT04305613 - Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
Recruiting NCT06036706 - Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma: N/A
Withdrawn NCT04593914 - A Novel Skin Barrier Protectant for Acute Radiodermatitis N/A
Recruiting NCT04110223 - Validation Studies of Biomarkers for Precision Radiation Oncology in Locally Advanced Solid Tumors
Active, not recruiting NCT02259218 - Metabolomic and Epigenetic Profiling of Bodyfluids From Lung and Brain Cancer Receiving Radiation Therapy
Recruiting NCT06073509 - Atrial Fibrillation and Other Cardiac Arrhythmias and Diseases After Radiotherapy for Breast Cancer : Watch Your HeaRT
Withdrawn NCT02017925 - Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation N/A
Completed NCT01170299 - Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer N/A
Completed NCT00974168 - Spinal Cord Compression Re-Treat Study Phase 2
Completed NCT00008398 - Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Phase 3
Enrolling by invitation NCT04047823 - Temperature and Injury in Radiotherapy Radiation Skin Injury